Study of amcenestrant (SAR439859) versus tamoxifen for patients with hormone receptor-positive (HR+) early breast cancer, who have discontinued adjuvant aromatase inhibitor therapy due to treatment-related toxicity

Trial Identifier: EFC16133
Sponsor: Sanofi
Collaborator:
Breast International Group (BIG)
Alliance Foundation Trials, LLC
European Organisation for Research and Treatment of Cancer (EORTC)
Start Date: February 2022
Primary Completion Date: October 2022
Study Completion Date: October 2022
Condition: Breast Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Chile, Reg Metropolitana de Santiago Santiago, Reg Metropolitana de Santiago, Chile
China Haikou, China, 570311